Recent News

• 06.10.2026 - MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
• 06.04.2026 - MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
• 06.03.2026 - MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
• 06.02.2026 - MAIA Biotechnology Announces Open Market Purchases by CEO and Director
• 06.01.2026 - MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology
• 04.16.2026 - MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer

Recent Filings

• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2026 - 8-K Current report
• 05.19.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.14.2026 - 8-K Current report